Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 1,901–2,000 of 2,576
Genetic markers in the diagnosis of Alzheimer's disease
Rogaeva, E. A., Tandon, A., & George‐Hyslop, P. S. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3304 · Cited by 13
“pathogenic presenilin mutations increase the production of Aβ42−43 peptides by altering the γ-secretase cleavage [10,21,34,115].”
The Pathophysiology of Alzheimer’s Disease
Selkoe, D. J. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-005-6_4 · Cited by 16
Self-citationYu, G., Chen, F., Nishimura, M., Steiner, H., Tandon, A., Kawarai, T., Arawaka, S., Supala, A., Song, Y., Rogaeva, E. A., et al. (2000) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2000.00301.x · Cited by 12
Effects of Specific Protease Inhibitors on Amyloid β-Protein 42 Secretion
Yamazaki, T., & Ihara, Y. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00031-1 · Cited by 9
Racchi, M., Johnston, J. A., Flood, F., Cowburn, R. F., & Govoni, S. M. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3380777 · Cited by 9
Strategies to alter the progression of Alzheimer's disease
Siman, R. G., & Scott, R. W. (1996) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(96)80070-x · Cited by 9
Putting presenilins centre stage
Hardy, J. (2007) · EMBO Reports · doi:10.1038/sj.embor.7400899 · Cited by 9
Self-citationSatoh, J., & Kuroda, Y. (2001) · Neuropathology · doi:10.1046/j.1440-1789.2001.00378.x · Cited by 10
Larner, A. J., & Rossor, M. N. (1997) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.7.10.1115 · Cited by 10
Chandrashekar, H., Simándi, Z., Choi, H., Ryu, H.-S., Waldman, A. J., Nikish, A., Muppidi, S. S., Gong, W., Paquet, D., & Phillips‐Cremins, J. E. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.27.582395 · Cited by 13
“We focused on the APP(Swe) FAD genotype because it is well documented to cause Aβ aggregates in early-onset FAD patients with severe cognitive defects 55, 56 .”
Aβ43 levels determine the onset of pathological amyloid deposition
Tambini, M. D., Yin, T., Yesiltepe, M., Breuillaud, L., Zehntner, S. P., d'Abramo, C., Giliberto, L., & D'Adamio, L. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104868 · Cited by 8
“PSEN1 and PSEN2 mutations reduce the activity and processivity of γ-secretase (8), leading to an alteration of the ratios between short and long forms of Aβ, in favor of long Aβ forms (9, 10).”
BackgroundCao, T., Yang, C., Zhang, J., Yan, Y., Chen, Z., Peng, X., Xia, C., Pan, M., Zou, C., & Lü, T. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107101 · Cited by 10
Pope, C. A., Wilkins, H., Swerdlow, R. H., & Wolfe, M. S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210366 · Cited by 9
“Presenilin is the catalytic component of γ-secretase, a protease complex that produces Aβ peptides of varying lengths [9], and FAD mutations in presenilins increase the critical ratio of Aβ42 to Aβ40 that determines aggregation [10, 11].”
A Hexameric Peptide Barrel as Building Block of Amyloid‐β Protofibrils
Lendel, C., Bjerring, M., Dubnovitsky, A. P., Kelly, R. T., Filippov, A. V., Antzutkin, O. N., Nielsen, N. C., & Härd, T. (2014) · Angewandte Chemie · doi:10.1002/ange.201406357 · Cited by 8
pH Dependence of Amyloid‐β Fibril Assembly Kinetics: Unravelling the Microscopic Molecular Processes
Tian, Y., & Viles, J. H. (2022) · Angewandte Chemie · doi:10.1002/ange.202210675 · Cited by 8
Oikawa, N., Goto, M., Ikeda, K., Taguchi, R., & Yanagisawa, K. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.07.027 · Cited by 8
Can blood amyloid levels be used as a biomarker for Alzheimer’s disease?
Yang, Y., Situmeang, R., & Ong, P. A. (2021) · Brain Science Advances · doi:10.26599/bsa.2021.9050004 · Cited by 8
How can secondary dementia prevention trials of Alzheimer's disease be clinically meaningful?
Liu, K. Y., Thambisetty, M., & Howard, R. J. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12788 · Cited by 9
Alzheimer’s disease: ageing-related or age-related? New hypotheses from an old debate
Bugiani, O. (2011) · Neurological Sciences · doi:10.1007/s10072-011-0614-4 · Cited by 10
The Role of Aβ and Tau Oligomers in the Pathogenesis of Alzheimer’s Disease
Bhaskar, K., & Lamb, B. T. (2011) · Springer eBooks · doi:10.1007/978-94-007-2774-8_5 · Cited by 10
The Genetics of Alzheimer's Disease
Brindle, N., & George‐Hyslop, P. S. (2003) · Humana Press eBooks · doi:10.1385/1-59259-195-7:23 · Cited by 8
Selkoe, D. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410529-4.00067-x · Cited by 9
Self-citationKumari, R., Chaudhary, A., & Mani, A. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e05546 · Cited by 9
“Rapid production of amyloid-beta takes place due to alteration in proteolysis of amyloid precursor protein (APP) caused by missense mutations in amyloid precursor protein (APP), PS-1 (presenilin-1), and PS-2 (presenilin-2) [10].”
BackgroundTargeting γ-secretase for familial Alzheimer’s disease
Wolfe, M. S. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-021-02744-3 · Cited by 8
Overview of the Alzheimer's Disease Pathology and Potential Therapeutic Targets
Cuello, A. C. (2007) · Springer eBooks · doi:10.1007/978-0-387-71522-3_1 · Cited by 8
“Mutations in PS1 (such as PS1 M146L) lead to the elevation of Aβ 1–42(43), by an as yet unknown mechanism (Borchelt et al., 1996; Citron et al., 1997; Duff et al., 1996; Scheuner et al., 1996), which assumes a gain of function of the γ-secretase activity.”
BackgroundVöglein, J., Willem, M., Trambauer, J., Schönecker, S., Dieterich, M., Biskup, S., Giudici, C., Utz, K. S., Oberstein, T. J., Brendel, M., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.08.034 · Cited by 8
Barritt, J. D., Younan, N. D., & Viles, J. H. (2017) · Angewandte Chemie · doi:10.1002/ange.201704618 · Cited by 10
Broeckhoven, C. V., & Kumar‐Singh, S. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s344 · Cited by 11
Familial Amyotrophic Lateral Sclerosis and Alzheimer’s Disease: Transgenic Models
Wong, P. C., Borchelt, D., Lee, M. K., Pardo, C. A., Thinakaran, G., Martin, L. J., Sisodia, S. S., & Price, D. L. (1998) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4869-0_9 · Cited by 8
Spatiotemporal Complexity of Fibroblast Networks Screens for Alzheimer's Disease
Chirila, F. V., Khan, T. K., & Alkon, D. L. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120745 · Cited by 11
“and are found in blood [1–4], saliva [5, 6], skin fibroblasts [7–10], or in the human lens [11].”
Alzheimer's Disease Therapeutics: New Approaches to an Ageing Problem
Small, D. H., Lošić, D., Martin, L. L., Turner, B. J., Friedhuber, A. M., & Aguilar, M. (2004) · IUBMB Life · doi:10.1080/15216540410001709211 · Cited by 8
Generation of Amyloid β Protein from a Presenilin-1 and βAPP Complex
Shizuka‐Ikeda, M., Matsubara, E., Ikeda, M., Kanai, M., Tomidokoro, Y., Ikeda, Y., Watanabe, M., Kawarabayashi, T., Harigaya, Y., Okamoto, K., et al. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6681 · Cited by 9
Evaluation of multiple presenilin 2 SNPs for association with early‐onset sporadic Alzheimer disease
Howell, W. M., & Brookes, A. J. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10533 · Cited by 8
Peptide Nucleic Acids Targeted to the Amyloid Precursor Protein
McMahon, B. M., Stewart, J. A., Fauq, A. H., Younkin, S. G., Younkin, L. H., & Richelson, E. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:3:261 · Cited by 8
“Aβ(1–40) and Aβ(1–42) levels were determined with a well-established sandwich ELISA system (Suzuki et al., 1994; Scheuner et al., 1996).”
MethodSelf-citationPascale, A., Bhagavan, S., Nelson, T. J., Neve, R. L., McPhie, D. L., & Etcheberrigaray, R. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00223-5 · Cited by 8
β‐Amyloid immunization approaches for Alzheimer's disease
Imbimbo, B. P. (2002) · Drug Development Research · doi:10.1002/ddr.10070 · Cited by 8
“2) All of the dominating autosomic mutations associated with the familial early-onset forms of AD are characterized by an overproduction of Ab42 [Citron et al., 1992, 1997; Scheuner et al., 1996; Suzuki et al., 1994; Borchelt et al., 1996].”
BackgroundChen, M. (1998) · Frontiers in bioscience · doi:10.2741/a249 · Cited by 8
Can Deposition of Amyloid Be Prevented in Alzheimer's Disease?a
Kisilevsky, R. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48465.x · Cited by 8
Biochemical Diagnostic Markers to Detect Early Alzheimer’s Disease
Lannfelt, L. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00012-8 · Cited by 8
Self-citationMetabolism of Presenilin 1: Influence of Presenilin 1 on Amyloid Precursor Protein Processing
Borchelt, D. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00026-8 · Cited by 8
Drug repositioning and indication discovery using description logics
Croset, S. (2014) · Apollo (University of Cambridge) · doi:10.17863/cam.15985 · Cited by 12
“Briefly, two macromolecules appear to be strongly involved in the disease: betaamyloid peptides, the main component of some of the deposits found in patients’ brains, and the Tau protein, responsible for stabilising microtubules (Scheuner et al., 1996) (Delacourte and Defossez, 1986).”
BackgroundIwata, N., Tsubuki, S., Sekiguchi, M., Watanabe-Iwata, K., Matsuba, Y., Kamano, N., Fujioka, R., Takamura, R., Watamura, N., Kakiya, N., et al. (2024) · Life Science Alliance · doi:10.26508/lsa.202402650 · Cited by 9
Viles, J. H. (2023) · Angewandte Chemie · doi:10.1002/ange.202215785 · Cited by 8
Alzheimer’s disease and clinical trials
Paul, D., Agrawal, R., & Singh, S. (2024) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2023-0264 · Cited by 9
Differential roles of Aβ processing in hypoxia-induced axonal damage
Christianson, M. G., & Lo, D. C. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.02.027 · Cited by 7
“…Stokin et al., 2005), and blockade of the enzymes necessary for Aβ production from APP (BACE1 and the γ-secretase complex (Hardy and Selkoe, 2002; Scheuner et al., 1996; Vassar et al., 1999) protects central axons fromdiverse stressors (Farah et al., 2011; Nikolaev et al., 2009; Yoon et al.,…”
BackgroundAn overview of in vitro research models for Alzheimer`s disease (AD)
Ntimi, C. M., Rosli, R., Adam, A., & Nordin, N. (2013) · Universiti Putra Malaysia Institutional Repository (Universiti Putra Malaysia) · Cited by 10
PEAβ Triggers Cognitive Decline and Amyloid Burden in a Novel Mouse Model of Alzheimer’s Disease
Camargo, L. C., Schöneck, M., Sangarapillai, N., Honold, D., Shah, N. J., Langen, K., Willbold, D., Kutzsche, J., Schemmert, S., & Willuweit, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137062 · Cited by 7
Sanchez, C., Nguyen, J., Baroutjian, A., Gill, S., McKenney, M. G., & Elkbuli, A. (2021) · Journal of Trauma Nursing · doi:10.1097/jtn.0000000000000606 · Cited by 7
Banerjee, R., & Gunawardena, S. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1202307 · Cited by 9
“FAD mutations alter toxic Aβ peptide fragments, which are generated by sequential proteolytic cleavage of APP by β-secretase followed by γ-secretase (Scheuner et al., 1996; Xia et al., 2015; Sun et al., 2017).”
BackgroundPro: Are we ready to translate Alzheimer's disease modifying therapies to people with Down syndrome?
Rafii, M. S. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0060-7 · Cited by 7
“Mutations of all genes known to be involved in familial AD - presenilin-1 (PSEN1), PSEN2, and amyloid precursor protein (APP) - contribute to increased absolute or relative production of the 42-amino-acid-length cleavage product of APP, beta-amyloid (Aβ), which is the main constituent of the amyloid plaques that chara…”
BackgroundGenetic dissection of neurodegenerative disease
Hardy, J. (2001) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(00)00013-x · Cited by 8
Self-citationLiu, Z., & Jia, J. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.06.054 · Cited by 7
Lahiri, D. K., Maloney, B., Rogers, J. T., & Ge, Y. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-68 · Cited by 7
“In addition, cases of late-onset AD have increased plasma levels of the forms of Aβ [54] specifically associated with the disease.”
BackgroundTwenty Years of Presenilins—Important Proteins in Health and Disease
Walter, J. (2015) · Molecular Medicine · doi:10.2119/molmed.2015.00163 · Cited by 9
Ohshima, Y., Iwata, K., Ibi, M., Matsumoto, M., Katsuyama, M., & Yabe‐Nishimura, C. (2018) · The Journal of Toxicological Sciences · doi:10.2131/jts.43.257 · Cited by 8
Wang, K., Sun, W., Xu, J., Qijing, Q., Yu, Z., Cheng, R., Zhang, L., Liu, S., Zhou, Z., Zhang, Y., et al. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200604174223 · Cited by 8
Dauch, P., Champigny, G., Ricci, J., & Checler, F. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(96)13296-1 · Cited by 7
Accumulation of Amyloid β Protein in Transgenic Mice
Shoji, M., Kawarabayashi, T., Sato, M., Sasaki, A., Matsubara, E., Igeta, Y., Kanai, M., Tomidokoro, Y., Shizuka, M., Ishiguro, K., et al. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00043-8 · Cited by 7
Smith, C., Stanyer, L., Betteridge, D. J., & Cooper, M. B. (2007) · Clinical Science · doi:10.1042/cs20070082 · Cited by 7
Protein Degradation in Human Disease
Plemper, R. K., & Hammond, A. L. (2002) · Progress in molecular and subcellular biology · doi:10.1007/978-3-642-56373-7_5 · Cited by 7
Etiological Clues from Gene Defects Causing Early Onset Familial Alzheimer’s Disease
Wasco, W., & Tanzi, R. E. (1997) · Humana Press eBooks · doi:10.1007/978-1-59259-471-9_1 · Cited by 7
Self-citationAlzheimer s disease and brain development common molecular pathways
Bowser, R. P. (1998) · Frontiers in bioscience · doi:10.2741/a267 · Cited by 7
Shen, Y., & Li, R. (1998) · Brain Research Bulletin · doi:10.1016/s0361-9230(97)00455-3 · Cited by 7
Sekijima, Y., Kametani, F., Tanaka, K., Okochi, M., Usami, M., Mori, H., Tokuda, T., & Ikeda, S.-I. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00348-1 · Cited by 7
The players on the γ-secretase team
Takashima, A., Shimojo, M., & Wolozin, B. L. (2006) · Nature Medicine · doi:10.1038/nm0706-766 · Cited by 7
Molecular genetics of early-onset Alzheimer's disease and frontotemporal lobar degeneration
Krüger, J. (2010) · Cited by 7
Säftig, P., & Strooper, B. D. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000408 · Cited by 7
Williams, J. H. (2003) · American Psychological Association eBooks · doi:10.1037/10480-025 · Cited by 7
CELLULAR AND MOLECULAR BASIS OF β-AMYLOID PRECURSOR PROTEIN METABOLISM
Greenfield, J. P., Gross, R. S., Gouras, G. K., & Xu, H. (2000) · Cited by 9
The Role of Genetics in Alzheimer's Disease and Parkinson's Disease
Porter, T., Gozt, A., Mastaglia, F. L., & Laws, S. M. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch15 · Cited by 6
Zebrafish Experimental Animal Models for AD: A Comprehensive Review
Sande, R., Godad, A. P., & Doshi, G. (2024) · Current Clinical Pharmacology · doi:10.2174/0127724328279684240104094257 · Cited by 7
Matsui, M., Murata, T., Kurobe-Takashima, Y., Ikeda, T., Noguchi‐Shinohara, M., Ono, K., Shidara, H., Otsuka, K., Kuriki, D., Suzuki, M., et al. (2024) · ACS Omega · doi:10.1021/acsomega.4c03353 · Cited by 8
Amyloid-independent pathogenesis for Alzheimer’s disease: implications for drug design
Wolfe, M. S. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03261-9 · Cited by 6
“These missense mutations, predominantly in PSEN1, were likewise found to increase the A β 42/A β 40 ratio [20 – 22].”
Alsiraey, N., & Dewald, H. D. (2024) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2024.112785 · Cited by 6
A new way APP mismetabolism can lead to Alzheimer's disease
Hardy, J., & Guerreiro, R. J. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100139 · Cited by 6
“…mutations and presenilin mutations increase the proportion of long Ab species by marginally altering the production from the g-secretase cleavage (Scheuner et al, 1996), and the Flemish and similar Alzheimer causing mutations appear to reduce flux through the competing a-secretase pathway (De…”
BackgroundSelf-citationNeuropathology of Alzheimer’s disease in Down syndrome
Mann, D. M. A. (2018) · CRC Press eBooks · doi:10.1201/9781315376875-2 · Cited by 6
Nutraceuticals: A Complementary Approach in the Management of Alzheimer’s Disease
Bansal, K., Mishra, S., Singh, V., & Bajpai, M. (2023) · Neurochemical Journal · doi:10.1134/s1819712423030030 · Cited by 6
Distribution of amyloid β protein precursor in the Alzheimer’s disease brain
Shoji, M., Kawarabayashi, T., Matsubara, E., Ikeda, M., Ishiguro, K., Harigaya, Y., & Okamoto, K. (2000) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2000.00636.x · Cited by 7
Finding chemopreventatives to reduce amyloid beta in yeast
Macreadie, I. G., Arvanitis, C., & Bharadwaj, P. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.177729 · Cited by 6
Darusman, H. S., Saepuloh, U., Mariya, S. S., Sajuthi, D., Schapiro, S. J., & Hau, J. (2021) · American Journal of Primatology · doi:10.1002/ajp.23296 · Cited by 8
“The amyloid Aβ disorder has been further characterized molecularly by demonstration of genetic mutations in amyloid precursor protein (APP) and the presenilin 1 and 2 components (Haque & Levey, 2019; Scheuner et al., 1996).”
BackgroundLinks Between Amyloid and Tau Biology in Alzheimer’s Disease and Their Cholinergic Aspects
Siegel, G. J., Chauhan, N. B., & Karczma, A. G. (2007) · Springer eBooks · doi:10.1007/978-0-387-46526-5_10 · Cited by 6
Endogenously generated amyloid-β increases stiffness in human neuroblastoma cells
Lu, Z., Li, H., Hou, C., Peng, Y., Long, J., & Liu, J. (2016) · European Biophysics Journal · doi:10.1007/s00249-016-1185-3 · Cited by 6
“The Swedish mutation of APP (APPswe) is one of the best-known genetic variations that can alter the cleavage process, causing elevated levels of Aβ production and leading to an early onset of AD (Scheuner et al. 1996).”
BackgroundHata, S., Hu, A., Piao, Y., Nakaya, T., Taru, H., Morishima‐Kawashima, M., Murayama, S., Nishimura, M., & Suzuki, T. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz297 · Cited by 6
“2C), consistent with that observed in familial AD subjects harboring pathogenic PSEN mutations (9,33,34).”
BackgroundServizi, S., Corrigan, R. R., & Casadesús, G. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200318151146 · Cited by 6
Extracellular Vesicles: The Next Frontier in Regenerative Medicine and Drug Delivery
Asadujjaman, M., Jang, D.-J., Cho, K. H., Hwang, S. R., & Jee, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3258-0_10 · Cited by 6
Genetics of Alzheimer’s disease — routes to the pathophysiology
Lannfelt, L., & Nordstedt, C. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6781-6_17 · Cited by 6
Self-citationChapter 2. Alzheimer's Disease: Recent Advances on the Amyloid Hypothesis
John, V., Latimer, L. H., Tung, J. S., & Dappen, M. S. (1997) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61460-8 · Cited by 7
Pastorino, L., Colciaghi, F., Marcon, G., Borroni, B., Cottini, E., Cattabeni, F., Padovani, A., & Luca, M. D. (2000) · Molecular Medicine · doi:10.1007/bf03401820 · Cited by 6
Aβ deposition is essential to AD neuropathology
Estus, S., Borchelt, D., Kindy, M. S., & Vassar, R. J. (2002) · Journal of Alzheimer s Disease · doi:10.3233/jad-2002-4302 · Cited by 6
“Because each of the mutated forms of these genes enhance the production of Aβ generally, or of the more “aggregatable” Aβ42 over Aβ40, the discovery of these genes has suggested that genes that impact on Aβ production or clearance could be critical to the disease [6,8,12,20,22,33,34,49,52,58].”
BackgroundEspinoza-Fonseca, M., & Trujillo-Ferrara, J. G. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.03.093 · Cited by 6
Implications of presenilin 1 mutations in Alzheimer’s disease
Komano, H., Sudoh, S., Kawamura, Y., Wang, R., & Yanagisawa, K. (1999) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(98)00135-3 · Cited by 9
Johnston, J. A., Lannfelt, L., Wiehager, B., O’Neill, C., & Cowburn, R. F. (1997) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(97)00074-4 · Cited by 6
Self-citationAmyloid-Beta, BDNF, and the Mechanism of Neurodegeneration in Alzheimer’s Disease
Rosa, E., & Fahnestock, M. L. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_43 · Cited by 7
Vogt, B. A., Vogt, L. J., & Hof, P. R. (2001) · Elsevier eBooks · doi:10.1016/b978-012351830-9/50012-3 · Cited by 6
Cell Cycle and Chromosome Segregation Defects in Alzheimer’s Disease
Potter, H. (2005) · Springer eBooks · doi:10.1007/0-387-29390-6_5 · Cited by 7
Molekulare Medizin der Alzheimer-Krankheit
Hoyer, S., Frölich, L., & Sandbrink, R. (1999) · Springer eBooks · doi:10.1007/978-3-662-07096-3_7 · Cited by 10
Phospholipid mass is increased in fibroblasts bearing the Swedish amyloid precursor mutation
Murphy, E. J., Huang, H., Cowburn, R. F., Lannfelt, L., & Gibson, G. E. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2005.10.012 · Cited by 6
Self-citationβ‐Amyloid Therapeutic Strategies for Alzheimer's Disease
Imbimbo, B. P., & Speroni, F. (2005) · Wiley eBooks · doi:10.1002/0471266949.bmc112 · Cited by 6
Manni, M. E., Cescato, R., & Paganetti, P. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00469-4 · Cited by 6
Hamazaki, H. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00157-4 · Cited by 7
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.